<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022983</url>
  </required_header>
  <id_info>
    <org_study_id>SIMPLE</org_study_id>
    <nct_id>NCT01022983</nct_id>
  </id_info>
  <brief_title>Preoperative Levosimendan and Heart Failure</brief_title>
  <acronym>PELS</acronym>
  <official_title>Preoperative Levosimendan in Patients With Heart Failure Undergoing Elective Noncardiac Surgery: A Randomized, Placebocontrolled Trial. SIMPLE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sykehuset i Vestfold HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sykehuset i Vestfold HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of Levosimendan given
      preoperative to patients with heart failure undergoing noncardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Not finding patients for including
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heartfailure - Highest NT-proBNP-value the first 7 days after surgery</measure>
    <time_frame>NT-proBNP 6 hours postoperative, 24 hours postoperative, 48 h postoperative, 72 h postoperative, 96 h postoperative, 120 h postoperative, 144 h postoperative and 168 h postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization</measure>
    <time_frame>Hospital stay - number of days patients are hospitalized</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of inotropes (dopamine, Norepinephrine)during postoperative unit stay. Mg/microgram</measure>
    <time_frame>After 16-18 hours, after 48 hours and every 24 hours if still in the PO-Unit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Visits or patients record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia</measure>
    <time_frame>7 days postoperative</time_frame>
    <description>Continous ECG first 24 hours an ECG every second day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial necrosis</measure>
    <time_frame>7 days postoperative</time_frame>
    <description>Troponin taken every day postoperative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Povidon, waterfree etanol, glucosis 5%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.</description>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_label>Povidon, waterfree etanol, glucosis 5%</arm_group_label>
    <other_name>Simdax</other_name>
    <other_name>ATC-nr.: C01C X08</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ml/kg/hours - same infusion rate as active comparator</description>
    <arm_group_label>Povidon, waterfree etanol, glucosis 5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute surgery. Hip Fracture

          -  Patient with cardiac failure (EF &lt; 35%) or known coronary disease

          -  At least 2 of 11 comorbidities

          -  Patient has to use at least one heart failure medication

          -  Symptoms of heart failure

          -  NT-proBNP &gt; 2000pg/ml

        Exclusion Criteria:

          -  &lt; 18 years old

          -  Participants in other pharmacological study

          -  Abuse of medicaments or alcohol

          -  Pregnant or breastfeeding women

          -  AMI at admission

          -  HOCM

          -  Serious aortic stenosis (&lt; 1 cm2)

          -  Sustained ventricular tachycardia

          -  Earlier episodes of &quot;torsades de pointes&quot;

          -  Sustained heartbeat &gt; 120/minute

          -  Systolic BP &lt; 90 mmHg

          -  Surgery planned not before 2 hours of study medication can be infused preoperative

          -  Cardiac surgery

          -  Dementia

          -  S-K &lt; 3 mmol/l

          -  Allergy levosimendan

          -  Serious liver failure (Known Class C Child-Pugh score)

          -  Serious kidney failure (GFR &lt; 30 ml/min.)

          -  Prolonged QTc-interval (male QTc &gt; 0,43 s, female QTc &gt; 0,45 s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Espen Lindholm, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vestfold Hospital trust, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Knut A Kirkebøen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital - Ullevål, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathias Kotyra, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mölndal hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Nydahl, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Örebro, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital - Ullevål</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestfold Hospital Trust</name>
      <address>
        <city>Tonsberg</city>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mölndal Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitety Hospital Örebro</name>
      <address>
        <city>Hudiksvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sykehuset i Vestfold HF</investigator_affiliation>
    <investigator_full_name>Espen Lindholm</investigator_full_name>
    <investigator_title>Seksjonsoverlege</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

